论文部分内容阅读
目的:探讨恩替卡韦治疗代偿期乙肝肝硬化患者过程中血清甲状腺激素的变化情况。方法:选取来我院进行治疗的乙肝肝硬化患者84例,84例患者在入院后,均给予支持治疗,维持水电解质平衡等综合治疗,在此治疗基础上再给予恩替卡韦片口服治疗,恩替卡韦0.5mg/次,1次/d,连续治疗24周时间。结果:患者经治疗后,有67例患者HBV-DNA转阴,有17例患者HBV-DNA未转阴。HBV-DNA转阴患者和HBV-DNA未转阴患者的血清甲状腺激素水平较治疗前有显著改善(P<0.05)。HBV-DNA转阴组患者治疗后的血清甲状腺激素水较HBV-DNA未转阴组患者显著升高(P<0.05)。患者经治疗后,HBV-DNA转阴患者和HBV-DNA未转阴患者的肝功能测定指标较治疗前均有显著改善(P<0.05)。HBV-DNA转阴组患者治疗后的肝功能测定指标较HBV-DNA未转阴组患者有显著提高(P<0.05)。结论:应用恩替卡韦治疗代偿期乙肝肝硬化,结果显示乙肝肝硬化患者的血清甲状腺激素水平得到显著的改善,表明代偿期乙肝肝硬化患者发生血清甲状腺激素紊乱时,不需要对其进行外源治疗,仅需要对原发病进行治疗就可以调整血清甲状腺激素水平。
Objective: To investigate the changes of serum thyroid hormones during entecavir treatment of patients with decompensated hepatitis B cirrhosis. Methods: Eighty-four patients with hepatitis B cirrhosis who were treated in our hospital were enrolled. Eighty-four patients were given supportive therapy after treatment to maintain the balance of electrolytes and electrolytes. On the basis of this therapy, oral administration of entecavir tablets was given. Entecavir 0.5 mg / time, 1 time / d, continuous treatment for 24 weeks. Results: After treatment, HBV-DNA of 67 patients turned negative, and HBV-DNA of 17 patients did not turn negative. The levels of serum thyroid hormone in HBV-DNA negative patients and HBV-DNA non-negative patients were significantly higher than those before treatment (P <0.05). Serum thyroid hormone levels in HBV-DNA negative patients were significantly higher than those in HBV-DNA non-negative patients (P <0.05). After treatment, the indexes of liver function in HBV-DNA negative patients and HBV-DNA non-negative patients were significantly improved (P <0.05). HBV-DNA negative group patients after treatment of liver function indicators than HBV-DNA non-negative group was significantly increased (P <0.05). Conclusion: Entecavir treatment of decompensated hepatitis B cirrhosis, the results showed that patients with hepatitis B cirrhosis serum thyroid hormone levels have been significantly improved, indicating compensatory hepatitis B cirrhosis patients with serum thyroid hormone disorders do not need to be exogenous Treatment, only need to treat the primary disease can be adjusted serum thyroid hormone levels.